Showing 1 - 5 of 5
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...
Persistent link: https://www.econbiz.de/10010281402
Persistent link: https://www.econbiz.de/10010281404
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. <p> Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...</p>
Persistent link: https://www.econbiz.de/10005771182
Background <p> Economic evaluation of treatments in multiple sclerosis (MS) presents a challenge. The disease affects a number of different body functions and leads to severe disability over time, without however a strong effect on mortality. At onset, the majority of patients will have...</p>
Persistent link: https://www.econbiz.de/10005771183
Many clinical trials are in progress which involve the collection of patient-level data on both the health outcome and resource use consequences of the health care interventions under evaluation. The overall aim of many such evaluations will be to undertake a cost-effectiveness analysis, which...
Persistent link: https://www.econbiz.de/10005649374